Authors: Robert W Harrison Kenneth W Mahaffey
Publish Date: 2011/11/17
Volume: 14, Issue: 1, Pages: 49-58
Abstract
Proton pump inhibitors and clopidogrel are commonly prescribed medications both alone and in combination In January of 2009 the US Food and Drug Administration and the European Medicines Agency issued warnings with regard to the concomitant use of clopidogrel and proton pump inhibitors Later that year these warnings were limited to the proton pump inhibitor omeprazole These warnings were largely based on invitro studies and observational analyses suggesting decreased efficacy of clopidogrel in the presence of proton pump inhibitors Recent literature has suggested there may not be a clinically meaningful interactionConflicts of interest RW Harrison none KW Mahaffey KW Mahaffey has been a consultant for AstraZeneca Bayer Boehringer Ingelheim BristolMyers Squibb Daiichi Sankyo Eli Lilly GlaxoSmithKline Johnson Johnson Merck Novartis OrthoMcNeil Pfizer Polymedix SanofiAventis and ScheringPlough and has received grant support from AstraZeneca Bayer Boehringer Ingelheim BristolMyers Squibb Daiichi Sankyo Eli Lilly GlaxoSmithKline Johnson Johnson Merck Novartis Portola Pozen Regado Biotechnologies SanofiAventis ScheringPlough and The Medicines Company
Keywords: